MolecularHealth Targets Cancer With New Tests

The Woodlands, Texas-based Molecular Health, the developer of medical decision support technology, said Wednesday that it has released two new diagnostic tests specifically aimed at improving cancer treatment. The company said its TreatmentMAP cancer treatment decision support offering uses genetic sequencing to help guide treatment options for individual cancer patients, using information on over 500 genes to figure out the possible treatments for cancer. The company said the tests can now be ordered in both the United States and in Europe. MolecularHealth is leveraging technology from the University of Texas MD Anderson Cancer Center, the U.S. Food and Drug Administration, and elsewhere to help develop its products.